CY1116887T1 - ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGY - Google Patents
ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGYInfo
- Publication number
- CY1116887T1 CY1116887T1 CY20151100984T CY151100984T CY1116887T1 CY 1116887 T1 CY1116887 T1 CY 1116887T1 CY 20151100984 T CY20151100984 T CY 20151100984T CY 151100984 T CY151100984 T CY 151100984T CY 1116887 T1 CY1116887 T1 CY 1116887T1
- Authority
- CY
- Cyprus
- Prior art keywords
- human
- antibodies
- relates
- pharmaceutical compositions
- present
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η εφεύρεση αφορά ανοσοθεραπευτικές συνθέσεις και μεθόδους για τη θεραπευτική αγωγή ασθενειών και διαταραχών των Β κυττάρων σε ανθρώπινα υποκείμενα, όπως, αλλά χωρίς περιορισμό εκεί, κακοήθειες Β κυττάρων, μέσω της χρήσης θεραπευτικών αντισωμάτων που προσδένονται στο ανθρώπινο CD 19 αντιγόνο και που κατά προτίμηση μεσολαβούν ανθρώπινη ADCC. Η παρούσα εφεύρεση αφορά φαρμακευτικές συνθέσεις οι οποίες αποτελούνται από ανθρώπινα ή εξανθρωπισμένα αντι-CD 19 αντισώματα του IgG1 ή IgG3 ανθρώπινου ισότυπου. Η παρούσα εφεύρεση αφορά φαρμακευτικές συνθέσεις οι οποίες αποτελούνται από ανθρώπινα ή εξανθρωπισμένα αντι-CD 19 αντισώματα του IgG2 ή IgG4 ανθρώπινου ισότυπου που κατά προτίμηση μεσολαβούν ανθρώπινη ADCC. Η παρούσα εφεύρεση αφορά επίσης φαρμακευτικές συνθέσεις οι οποίες αποτελούνται από αντι-CD19 αντισώματα του IgG1, IgG2, IgG3, ή IgG4 ισότυπου τα οποία μεσολαβούν ανθρώπινη ADCC. Σε προτιμώμενες υλοποιήσεις, η παρούσα εφεύρεση αφορά φαρμακευτικές συνθέσεις οι οποίες αποτελούνται από μονοκλωνικά ανθρώπινα, εξανθρωπισμένα, ή χιμαιρικά αντι-CD 19 αντισώματα.The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, through the use of therapeutic antibodies that bind to the human CD 19 antigen and preferably mediate ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the human IgG1 or IgG3 isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the human IgG2 or IgG4 isotype preferably mediated by human ADCC. The present invention also relates to pharmaceutical compositions comprising anti-CD19 antibodies of human ADCC mediated IgG1, IgG2, IgG3, or IgG4 isotype. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65358705A | 2005-02-15 | 2005-02-15 | |
| US70206305A | 2005-07-22 | 2005-07-22 | |
| EP06735370.6A EP1853718B1 (en) | 2005-02-15 | 2006-02-15 | Anti-cd19 antibodies and uses in oncology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116887T1 true CY1116887T1 (en) | 2017-04-05 |
Family
ID=58487006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100984T CY1116887T1 (en) | 2005-02-15 | 2015-11-04 | ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGY |
Country Status (1)
| Country | Link |
|---|---|
| CY (1) | CY1116887T1 (en) |
-
2015
- 2015-11-04 CY CY20151100984T patent/CY1116887T1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006089133A3 (en) | Anti-cd19 antibodies and uses in oncology | |
| NL301196I2 (en) | inebilizumab | |
| WO2006121852A3 (en) | Anti-cd19 antibody therapy for autoimmune disease | |
| CY1119454T1 (en) | ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA | |
| TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
| WO2006133450A3 (en) | Anti-cd19 antibody therapy for the transplantation | |
| HRP20191609T1 (en) | Protein | |
| WO2005103081A3 (en) | Human monoclonal antibodies against cd20 | |
| CY1115572T1 (en) | CXCR4 ANTIBODIES AND USE OF THESE FOR CANCER TREATMENT | |
| UA90457C2 (en) | Human monoclonal antibody that specifically binds to human m-csf | |
| ATE557042T1 (en) | ANTI-MYOSTATIN ANTIBODIES | |
| UA109633C2 (en) | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
| UA90082C2 (en) | SEPARATE MONOCLONAL ANTIBODY OF HUMANS SPECIFICALLY Binding TO CD25 HUMANS AND INHIBITING IL-2 Binding TO CD25 | |
| EA202091590A1 (en) | ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION OPTIONS | |
| CY1115456T1 (en) | METHOD OF ADJUSTMENT OF ANTI-ANTI-IL-5 | |
| ATE517920T1 (en) | HUMANIZED ANTIBODIES AGAINST INTERFERON ALPHA RECEPTOR-1 (IFNAR-1) | |
| PL374587A1 (en) | Pharmaceutical compositions directed to erb-b1 receptors | |
| MX2023001776A (en) | Antibodies against ilt2 and use thereof. | |
| EA200702634A1 (en) | HUMANIZED ANTIBODIES SPECIFIC FOR NOGO-A AND THEIR PHARMACEUTICAL APPLICATIONS | |
| WO2008042941A3 (en) | Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease | |
| ATE525401T1 (en) | MHC CLASS I AND II PEPTIDE ANTIGENS DERIVED FROM TUMOR ANTIGEN 5T4 | |
| CY1116887T1 (en) | ANTI-CD19 ANTIBODIES AND USES IN ONCOLOGY | |
| EA202190387A1 (en) | ANTIBODY TO HUMAN CD38 AND ITS USE | |
| UA84539C2 (en) | Human monoclonal antibody that specifically binds to cd40, pharmaceutical composition containing thereof and use of antibody for production of medicinal agent for treatment of cd40- negative human tumor | |
| UA102085C2 (en) | ISOLATED MONOCLONAL ANTIBODY THAT BINDS TO hGM-CSF AND COMPOSITION COMPRISING SAME |